Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5);Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 510-517

  Britten, Carolyn D ^a,e   Adjei, Alex A ^b   Millham, Robert ^c   Houk, Brett E ^c   Borzillo, Gary ^c   Pierce, Kristen ^c   Wainberg, Zev A ^a   LoRusso, Patricia M ^d  

^a UCLA MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

mTOR; Phase I; PI3K; Small molecule

Indexed keywords

ANTINEOPLASTIC AGENT; C PEPTIDE; GLUCOSE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; 2-AMINO-8-(4-(2-HYDROXYETHOXY)CYCLOHEXYL)-6-(6-METHOXYPYRIDIN-3-YL)-4-METHYLPYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ARTICLE; CANCER INHIBITION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INSULIN BLOOD LEVEL; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; METABOLISM; NEOPLASMS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; PYRIDONES; PYRIMIDINES; TOR SERINE-THREONINE KINASES;

EID: 84904622446     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0069-6     Document Type: Erratum

References (26)

1. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
2. Ogita S, Lorusso P (2011) Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol 6:103-117
3. Ihle NT, Powis G (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8:1-9
4. Arcaro A, Guerreiro AS (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 8:271-306 (Pubitemid 351210980)
5. Rodriguez-Viciana P, Warne PH, Dhand R et al (1994) Phosphatidylinositol- 3-OH kinase as a direct target of Ras. Nature 370:527-532 (Pubitemid 24264918)
6. Abraham RT, Eng CH (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 12:209-222 (Pubitemid 351284963)
7. Markman B, Dienstmann R, Tabernero J (2010) Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 1:530-543
8. Yuan J, Mehta PP, Yin MJ et al (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10:2189-2199
9. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
10. Rodon J, Dienstmann R, Serra Vet al (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10:143-153
11. Knight ZA, Gonzalez B, Feldman ME et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747
12. Foukas LC, Claret M, Pearce W et al (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366-370 (Pubitemid 44050203)
13. Busaidy NL, Farooki A, Dowlati A et al (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30:2919-2928
14. Millham R, Houk B, Borzillo G, et al (2011) First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology. Mol Cancer Ther 10:Abst. A167
15. Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022-4028
16. Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496-3499 (Pubitemid 46572540)
17. Das Thakur M, Salangsang F, Landman AS et al (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494:251-255
18. Britten CD (2013) PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 71:1395-1409
19. Burris HA 3rd (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71:829-842
20. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3KmTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320-328
21. Kinross KM, Brown DV, Kleinschmidt M et al (2011) In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras (G12D); Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 10:1440-1449
22. Simmons BH, Lee JH, Lalwani K et al (2012) Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice. Cancer Chemother Pharmacol 70:213-220
23. Herzog A, Bian Y, Vander Broek R et al (2013) PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 19:3808-3819
24. Wander SA, Zhao D, Besser AH et al (2013) PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat 138:369-381
25. Mallon R, Feldberg LR, Lucas J et al (2011) Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 17:3193-3203
26. Canon JL, Bergh J, Saura C et al (2012) Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data. Cancer Res 72:572S, Abst. OT2-3-02